Distinct Gene Expression Signatures Characterize Strong Clinical Responders Versus Nonresponders to Canakinumab in Children With Systemic Juvenile Idiopathic Arthritis.
Emely L VerweyenAlex PickeringAlexei A GromGrant S SchulertPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2021)
Here, we identify a gene signature in systemic JIA patients prior to receiving treatment that distinguishes strong responders to canakinumab from nonresponders. Further prospective studies are needed to assess the utility of these insights for treatment decisions in systemic JIA and to track the association of up-regulated type I IFN signatures with systemic JIA complications.
Keyphrases
- juvenile idiopathic arthritis
- gene expression
- end stage renal disease
- genome wide
- disease activity
- newly diagnosed
- ejection fraction
- young adults
- chronic kidney disease
- risk factors
- rheumatoid arthritis
- immune response
- peritoneal dialysis
- systemic lupus erythematosus
- patient reported outcomes
- drug induced
- patient reported
- smoking cessation